TNF and inflammatory bowel disease: Regarding data concerning new biologic therapies, a recent multicenter retrospective study included 538 IBD patients and compared the risks of incident cancer in patients with a history of non-GI cancer and receiving thiopurines (27%), anti-TNF (21%), or VDZ (9%).